Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2017 08:00 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Announces that Rutgers, The State University at New Jersey, Plans Study Utilizing Atossa’s Microcatheter Technology

SEATTLE, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
October 02, 2017 08:00 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer

SEATTLE, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
September 29, 2017 08:00 ET | Source: Atossa Genetics, Inc.

Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017

SEATTLE, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
September 25, 2017 08:00 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Announces Upcoming Phase 2 Study of Topical Endoxifen

SEATTLE, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
September 14, 2017 13:00 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Topical Endoxifen

***All Objectives Successfully Met*** Conference Call To Be Held Today at 2pm Eastern Time SEATTLE, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage...
September 11, 2017 08:15 ET | Source: Atossa Genetics, Inc.

Atossa Genetics To Host Conference Call to Announce Preliminary Results from Phase 1 Study of Topical Endoxifen Thursday, September 14, 2017 at 2 pm EDT

SEATTLE, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...
August 14, 2017 16:30 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Announces Second Quarter 2017 Financial Results And Provides Company Update

SEATTLE, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) today announced Second Quarter ended June 30, 2017 financial results and provided an update on recent company...
July 25, 2017 09:16 ET | Source: Atossa Genetics, Inc.

Atossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study

SEATTLE, July 25, 2017 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other...